Long-Term Specified Drug Use-results Survey of Betanis Tablets

N/ACompletedNCT01901120

Astellas Pharma Inc1,263 enrolled

Overview

This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.

Study Type

OBSERVATIONAL

Enrollment

1,263

Conditions

Overactive Bladder

Interventions

BetanisDRUG

oral

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.

Locations (8)

Unnamed facility

Chūbu, Chubu, Japan

Unnamed facility

Chugoku, Chugoku, Japan

Unnamed facility

Hokkaido, Hokkaido, Japan

Unnamed facility

Kansai, Kansai, Japan

Unnamed facility

Outcomes

Primary Outcomes

Occurrence of adverse events

Time frame: Up to 36 months after treatment

Secondary Outcomes

Overactive Bladder Symptom Score (OABSS)

Time frame: At the start of treatment and 3, 6, 12, 18, 24, 30, and 36 months after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.